New! View global litigation for patent families

WO2004002419A3 - Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment - Google Patents

Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment

Info

Publication number
WO2004002419A3
WO2004002419A3 PCT/US2003/020408 US0320408W WO2004002419A3 WO 2004002419 A3 WO2004002419 A3 WO 2004002419A3 US 0320408 W US0320408 W US 0320408W WO 2004002419 A3 WO2004002419 A3 WO 2004002419A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
phosphate
carvedilol
salts
solvates
dihydrogen
Prior art date
Application number
PCT/US2003/020408
Other languages
French (fr)
Other versions
WO2004002419A2 (en )
Inventor
Christopher S Brook
Wei Chen
Orco Philip C Dell
Lee M Katrincic
Ann Marie Louvet
Choon K Oh
Paul G Spoors
Christopher Werner
Original Assignee
Christopher S Brook
Wei Chen
Orco Philip C Dell
Lee M Katrincic
Ann Marie Louvet
Choon K Oh
Sb Pharmco Inc
Paul G Spoors
Christopher Werner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Abstract

The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy) ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat hypertension, congestive heart failure and angina, etc.
PCT/US2003/020408 2002-06-27 2003-06-27 Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment WO2004002419A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US39217502 true 2002-06-27 2002-06-27
US60/392,175 2002-06-27

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CA 2492060 CA2492060C (en) 2002-06-27 2003-06-27 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
US10518654 US7268156B2 (en) 2002-06-27 2003-06-27 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
KR20137033808A KR20140006111A (en) 2002-06-27 2003-06-27 Carvedilol phosphate salts and(or) solvates thereof, corresponding compositions, and(or) methods of treatment
KR20137008295A KR101468827B1 (en) 2002-06-27 2003-06-27 Carvedilol Phosphate Salts and(or) Solvates Thereof, Corresponding Compositions, and(or) Methods of Treatment
EP20030762176 EP1534270A4 (en) 2002-06-27 2003-06-27 Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment
JP2004518025A JP2005533823A (en) 2002-06-27 2003-06-27 Carvedilol phosphate and / or a solvate, corresponding compositions, and / or treating
US11767581 US7759384B2 (en) 2002-06-27 2007-06-25 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
US11767578 US7893100B2 (en) 2002-06-27 2007-06-25 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
US11767573 US7626041B2 (en) 2002-06-27 2007-06-25 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
US11767566 US20070259940A1 (en) 2002-06-27 2007-06-25 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
US11767586 US7902378B2 (en) 2002-06-27 2007-06-25 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US11767581 Division US7759384B2 (en) 2002-06-27 2007-06-25 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
US11767578 Division US7893100B2 (en) 2002-06-27 2007-06-25 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
US11767573 Division US7626041B2 (en) 2002-06-27 2007-06-25 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment

Publications (2)

Publication Number Publication Date
WO2004002419A2 true WO2004002419A2 (en) 2004-01-08
WO2004002419A3 true true WO2004002419A3 (en) 2004-06-03

Family

ID=30000823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020408 WO2004002419A3 (en) 2002-06-27 2003-06-27 Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment

Country Status (7)

Country Link
US (6) US7268156B2 (en)
EP (1) EP1534270A4 (en)
JP (3) JP2005533823A (en)
KR (3) KR101468827B1 (en)
CN (6) CN103288715A (en)
CA (1) CA2492060C (en)
WO (1) WO2004002419A3 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245974C (en) * 2000-06-28 2006-03-22 特瓦制药工业有限公司 Carvedilol
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
KR20040077872A (en) 2002-01-15 2004-09-07 테바 파마슈티컬 인더스트리즈 리미티드 Crystalline solids of carvedilol and processes for their preparation
US20050148779A1 (en) * 2002-04-30 2005-07-07 Wei Chen Carvedilol monocitrate monohydrate
US20050261355A1 (en) 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
CN103288715A (en) 2002-06-27 2013-09-11 史密斯克莱.比奇曼(科克)有限公司 Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment
CN1694959B (en) 2002-09-13 2013-09-18 雷普利瑟公司 Non-sequence complementary antiviral oligonucleotides
WO2005051325A3 (en) * 2003-11-25 2005-08-11 Matthew D Burke Carvedilol compositions methods of treatment and delivery
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
WO2005051383A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
KR20070088507A (en) * 2005-06-09 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 Crystalline forms of carvedilol and processes for their preparation
WO2007144900A3 (en) * 2006-06-14 2009-04-16 Matrix Lab Ltd Carvedilol phosphate sesquihydrate
EP1991527A2 (en) * 2006-06-28 2008-11-19 Teva Pharmaceutical Industries Ltd Polymorphous forms of carvedilol phosphate
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008084494A1 (en) * 2007-01-08 2008-07-17 Matrix Laboratories Limited Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
EP2114881A1 (en) * 2007-02-26 2009-11-11 Teva Pharmaceutical Industries Ltd. Process for the purification of carvedilol or its salts thereof
WO2008104990A1 (en) * 2007-02-27 2008-09-04 Lupin Limited Amorphous carvedilol dihydrogen phosphate
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
WO2008142703A1 (en) * 2007-05-17 2008-11-27 Wanbury Limited A novel cost effective process for production of carvedilol phosphate
EP2014649A1 (en) * 2007-06-27 2009-01-14 Inke, S.A. Novel amorphous carvedilol dihydrogen phosphate
WO2009008009A4 (en) * 2007-07-11 2009-03-05 Lupin Ltd Novel crystalline form b of carvedilol dihydrogen phosphate
US20100076047A1 (en) * 2007-08-20 2010-03-25 Sankar Reddy Budidet Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt
EP2195292B1 (en) * 2007-08-21 2013-10-02 Lupin Ltd. Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer
US20090076283A1 (en) * 2007-09-07 2009-03-19 Scinopharm Taiwan Ltd. Method of crystallizing carvedilol phosphate and the product thereof
US20090111998A1 (en) * 2007-10-25 2009-04-30 Srinivas Reddy Gade Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof
WO2009122425A1 (en) * 2008-04-04 2009-10-08 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
US7763645B2 (en) * 2008-05-23 2010-07-27 Wanbury Limited Carvedilol dihydrogen phosphate monohydrate
CN101891671B (en) * 2010-07-26 2012-06-27 天津大学 Crystals of carvidilol dihydric phosphate and preparation method thereof
US8492426B1 (en) * 2012-07-12 2013-07-23 Anis Ahmad Use of carvedilol for treatment of diabetes mellitus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087837A1 (en) * 2000-05-18 2001-11-22 A/S Gea Farmaceutisk Fabrik Process and intermediates for the preparation of 1-(9h-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol or acid addition salts thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053067A (en) * 1973-06-25 1977-10-11 Westinghouse Electric Corporation Fuel transfer system for a nuclear reactor
DE2815926A1 (en) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh New carbazolyl (4) -oxy-propanolamine derivatives, processes for their preparation and medicines containing compounds
DE3319027A1 (en) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh A process for the preparation of optically active carbazole derivatives, new R- and S-carbazole derivatives, and pharmaceutical compositions containing these compounds
US4985464A (en) 1984-05-23 1991-01-15 Rudolf Happle Drug compositions for local treatment of alopecia areata
US5405863A (en) 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
US5308862A (en) 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US20010011099A1 (en) 1995-05-30 2001-08-02 Smithkline Beecham Corporation Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds
EP0910374A1 (en) 1996-07-13 1999-04-28 Boehringer Mannheim Gmbh Pharmaceutical formulations for topical application containing as an active ingredient a carbazolyl-(4)-oxy-propanol amine derivate
US6096777A (en) 1996-08-23 2000-08-01 Boehringer Mannheim Pharmaceuticals Corporation Method for inhibiting the expression of Fas
KR20000048967A (en) 1996-10-09 2000-07-25 제이 베리 부조가니 Method for inhibiting stress-activated protein kinases
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
EP0893440A1 (en) * 1997-07-22 1999-01-27 Boehringer Mannheim Gmbh Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
DE69828413T2 (en) 1997-08-29 2005-12-08 Pfizer Inc. Containing atorvastatin combination therapy and bluddrucksenkendes medium
CN1281334A (en) 1997-10-15 2001-01-24 泊灵格曼海姆药品公司及史密斯克莱恩贝克曼公司 Method for treating Alzheimer's disease
US6541479B1 (en) 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
JP3947654B2 (en) 1998-04-09 2007-07-25 ロシュ ダイアグノスティックス ゲーエムベーハー Carvedilol formulation
US6852337B2 (en) 1998-04-09 2005-02-08 Roche Diagnostics Gmbh Carvedilol-galenics
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
DE19833119A1 (en) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Storage-stable injectable solution of vasodilator and beta blocker Carvedilol contains buffer, organic solvent, antioxidant and complexing agent
ES2195638T3 (en) 1998-11-27 2003-12-01 Hoffmann La Roche Preparations of pharmaceutical combinations in solid dosage form containing carvedilol and hydrochlorothiazide that.
CA2392085A1 (en) 1999-11-15 2001-05-25 Smithkline Beecham Corporation Carvedilol methanesulfonate
US20020068740A1 (en) 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
US20010036959A1 (en) 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
DE60105996T2 (en) 2000-04-03 2006-03-09 F. Hoffmann-La Roche Ag Concentrated solutions of carvedilol
WO2001078725A3 (en) 2000-04-13 2001-12-20 Dalen Frans Van Modified release formulations containing a hypnotic agent
US20020054911A1 (en) 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
CN1245974C (en) 2000-06-28 2006-03-22 特瓦制药工业有限公司 Carvedilol
US20040019096A1 (en) 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
EP1385509A4 (en) 2001-04-02 2004-06-30 Smithkline Beecham Corp Method of treatment
WO2002092078A1 (en) 2001-05-17 2002-11-21 Sun Pharamceutical Industries Limited Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
FI20011464A0 (en) 2001-07-04 2001-07-04 Orion Corp Combination Therapy for the treatment of heart failure
US20040152756A1 (en) 2002-07-15 2004-08-05 Wei Chen Carvedilol polymorph
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
DK1429734T3 (en) 2001-09-21 2008-05-13 Egalet As Solid dispersions of carvedilol for the Controlled Release
WO2003029214A1 (en) 2001-09-28 2003-04-10 F. Hoffmann-La Roche Ag Pseudopolymorphic forms of carvedilol
WO2003028718A1 (en) 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
WO2003028645A3 (en) 2001-10-01 2004-03-25 Vlassios Andronis Novel compositions of carvedilol
US20040186158A1 (en) 2001-10-02 2004-09-23 Oh Choon K. Novel composition of carvedilol
KR20040077872A (en) 2002-01-15 2004-09-07 테바 파마슈티컬 인더스트리즈 리미티드 Crystalline solids of carvedilol and processes for their preparation
US20050148779A1 (en) 2002-04-30 2005-07-07 Wei Chen Carvedilol monocitrate monohydrate
CN103288715A (en) * 2002-06-27 2013-09-11 史密斯克莱.比奇曼(科克)有限公司 Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment
KR20040010306A (en) 2002-07-22 2004-01-31 (주)나노하이브리드 A Hybrid Of Itraconazole, Cyclosporine Or Carvedilol With A Layered Silicate And A Process For Preparing The Same
ES2204303B2 (en) * 2002-08-07 2004-12-16 Laboratorios Vita, S.A. Process for preparing a pharmaceutically active compound.
EP1530458A1 (en) 2002-08-14 2005-05-18 Ranbaxy Laboratories, Ltd. Extended release matrix tablets
WO2004041252A1 (en) 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
WO2004056336A3 (en) 2002-12-20 2004-09-10 Ranbaxy Lab Ltd Controlled release, multiple unit drug delivery systems
WO2005051325A3 (en) * 2003-11-25 2005-08-11 Matthew D Burke Carvedilol compositions methods of treatment and delivery
WO2005051383A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
US20050175695A1 (en) 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087837A1 (en) * 2000-05-18 2001-11-22 A/S Gea Farmaceutisk Fabrik Process and intermediates for the preparation of 1-(9h-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol or acid addition salts thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1534270A2 *

Also Published As

Publication number Publication date Type
US7268156B2 (en) 2007-09-11 grant
US20050240027A1 (en) 2005-10-27 application
US7626041B2 (en) 2009-12-01 grant
CN103288714A (en) 2013-09-11 application
KR20130042047A (en) 2013-04-25 application
CN101898995A (en) 2010-12-01 application
US20070244181A1 (en) 2007-10-18 application
CN1678305A (en) 2005-10-05 application
EP1534270A2 (en) 2005-06-01 application
EP1534270A4 (en) 2006-05-17 application
JP2011088917A (en) 2011-05-06 application
CN103333099A (en) 2013-10-02 application
KR101468827B1 (en) 2014-12-03 grant
CA2492060C (en) 2011-11-01 grant
US20080262069A1 (en) 2008-10-23 application
KR20140006111A (en) 2014-01-15 application
WO2004002419A2 (en) 2004-01-08 application
JP2005533823A (en) 2005-11-10 application
US20070238774A1 (en) 2007-10-11 application
CN103254114A (en) 2013-08-21 application
US20070259940A1 (en) 2007-11-08 application
US7759384B2 (en) 2010-07-20 grant
CN103288715A (en) 2013-09-11 application
CN101898995B (en) 2013-05-01 grant
JP2013241450A (en) 2013-12-05 application
KR20110134952A (en) 2011-12-15 application
US20070244182A1 (en) 2007-10-18 application
US7902378B2 (en) 2011-03-08 grant
JP5422545B2 (en) 2014-02-19 grant
CA2492060A1 (en) 2004-01-08 application
US7893100B2 (en) 2011-02-22 grant

Similar Documents

Publication Publication Date Title
WO2004056786A3 (en) Pyrimidine derivates for the treatment of abnormal cell growth
CA2463989A1 (en) Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
WO2004067003A1 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
WO2006077821A1 (en) Aromatic sulfone compound as aldosterone receptor modulator
WO2003066099A1 (en) 2,4,6-triamino-1,3,5-triazine derivative
WO2003068959A1 (en) Novel screening method
WO2007059257A3 (en) N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
WO2004048339A1 (en) Isoquinoline compounds and medicinal use thereof
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
Augustyns et al. Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV
WO2005000839A1 (en) Process for producing 3-acylaminobenzofuran-2-carboxylic acid derivative
WO1997005135A1 (en) Pyrrolidine derivatives having phospholipase a2 inhibitory activity
WO2006023750A3 (en) Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006023944A3 (en) Pulmonary delivery of inhibitors of phosphodiesterase type 5
WO2005123703A8 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
WO2004074244A3 (en) Pyrimidine compounds
WO1999026918A1 (en) Biphenylamidine derivatives
WO1999026919A1 (en) Biphenylamidine derivatives
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2003106416A3 (en) Chemical process
WO2001005428A1 (en) Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
WO2004037159A3 (en) Compounds, compositions and methods for modulating fat metabolism
WO2006034235A3 (en) Substituted quinoline and quinazoline inhibitors of quinone reductase 2
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
WO2001060814A3 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BR BZ CA CN CO CR CU DM DZ EC GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ OM PH PL RO SC SG TN TT UA US UZ VN YU ZA

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 200410011

Country of ref document: ZA

Ref document number: 2004/10011

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 537161

Country of ref document: NZ

Ref document number: 2003248746

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10518654

Country of ref document: US

Ref document number: 165814

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/012923

Country of ref document: MX

Ref document number: 2492060

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1-2004-502085

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 1020047021135

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004518025

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003762176

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038202301

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020047021135

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003762176

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: PI0312102

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 12008502076

Country of ref document: PH